title: Nilotinib versus imatinib for GIST - Authors' reply.
authors.affiliation: Centre Leon Berard, 69008 Lyon, France. Electronic address: jean-yves.blay@lyon.unicancer.fr.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Blay
authors.affiliation: Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
authors.forename: Eunjuh
authors.initials: E
authors.lastname: Hurh
authors.affiliation: Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Green
authors.affiliation: Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Novick
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001549:Benzamides / Q000008:administration & dosage*; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines